Association between tumor mutational burden (TMB) assessed by whole-exome sequencing (WES) and outcomes of pembrolizumab (pembro) monotherapy

被引：5
|
作者：
Cristescu, Razvan [1 ]
Aurora-Garg, Deepti [1 ]
Albright, Andrew [1 ]
Xu, Lei [1 ]
Liu, Xiao Qiao [2 ]
Loboda, Andrey [1 ]
Lang, Lixin [1 ]
Jin, Fan [1 ]
Snyder, Alexandra [1 ]
Lunceford, Jared [1 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] MSD China, Beijing, Peoples R China
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-LB-261
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-261
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A study of tumor neoantigen burden and HLA-LOH by whole-exome sequencing to characterize immune biomarkers of lung cancer.
    Wang, Wei
    Liao, Wenting
    Zhen, Baoling
    Ji, Tianrong
    Du, Chen
    Cheng, Shaochen
    Chen, Yaru
    Yang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Comparison of the tumor mutation burden (TMB) analysis results between a targeted next-generation sequencing method and the conventional WES method.
    Cai, Yuhang
    Wang, Chunli
    Zhou, Shuang
    Wang, Zhe
    Mao, Mao
    Ye, Mingzhi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC)
    Foran, James M.
    Heckman, Michael G.
    Cherukuri, Yesesri
    Wieczorek, Mikolaj
    Rahman, Zaid Abdel
    Jiang, Liuyan
    Murthy, Hemant S.
    Finn, Laura
    Badar, Talha
    Sproat, Lisa Z.
    Lou, Yanyan
    Cerhan, James R.
    Asmann, Yan
    BLOOD, 2021, 138
  • [34] Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing
    Hatakeyama, Keiichi
    Nagashima, Takeshi
    Urakami, Kenichi
    Ohshima, Keiichi
    Serizawa, Masakuni
    Ohnami, Sumiko
    Shimoda, Yuji
    Ohnami, Shumpei
    Maruyama, Koji
    Naruoka, Akane
    Akiyama, Yasuto
    Kusuhara, Masatoshi
    Mochizuki, Tohru
    Yamaguchi, Ken
    BIOMEDICAL RESEARCH-TOKYO, 2018, 39 (03): : 159 - +
  • [35] Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
    Noskova, Hana
    Kyr, Michal
    Pal, Karol
    Merta, Tomas
    Mudry, Peter
    Polaskova, Kristyna
    Ivkovic, Tina Catela
    Adamcova, Sona
    Hornakova, Tekla
    Jezova, Marta
    Kren, Leos
    Sterba, Jaroslav
    Slaby, Ondrej
    CANCERS, 2020, 12 (01)
  • [36] Assessment of tumor mutation burden (TMB) based on whole exome sequencing using extracellular vesicles-derived DNA obtained from bronchoalveolar lavage fluid (BALF) in advanced NSCLC patients treated with pembrolizumab
    Kim, Heejoung
    Hur, Jaeyoung
    Kim, Wan Seop
    Kim, In Ae
    Park, Dong Il
    Oh, In-Jae
    Lee, Kye Young
    CANCER RESEARCH, 2023, 83 (07)
  • [37] Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
    Willoughby, David
    Bognar, Ernest
    Stanbery, Laura
    Nagel, Casey
    Wallraven, Gladice
    Pruthi, Aman
    Bild, Nicholas
    Stamper, Ericca
    Rao, Donald
    Walter, Adam
    Nemunaitis, John
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [38] Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI)
    Xavier, Camila Braganca
    Guardia, Gabriela
    Lopes, Carlos Diego Holanda
    Awni, Beatriz Mendes
    Campos, Eduardo Felicio
    Alves, Joao Pedro
    Camargo, Anamaria Aranha
    Galante, Pedro Alexandre Favoretto
    Jardim, Denis L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
    Lin, H.
    Ran, W.
    Chen, X.
    Wang, B.
    Yang, P.
    Li, Y.
    Xiao, Y.
    Wang, X.
    Li, G.
    Wang, L.
    Han, Y.
    Peng, Y.
    Lang, J.
    Liang, Y.
    Tian, G.
    Yuan, D.
    Yang, J.
    Deng, C.
    Xing, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Comparing tumor mutation burden detection between whole exome and target enrichment sequencing among Taiwanese breast cancers
    Huang, C-C
    Huang, C-S
    CANCER RESEARCH, 2019, 79 (04)
12345